[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2009017719A3 - Modulators of ccr9 receptor and methods of use thereof - Google Patents

Modulators of ccr9 receptor and methods of use thereof Download PDF

Info

Publication number
WO2009017719A3
WO2009017719A3 PCT/US2008/009142 US2008009142W WO2009017719A3 WO 2009017719 A3 WO2009017719 A3 WO 2009017719A3 US 2008009142 W US2008009142 W US 2008009142W WO 2009017719 A3 WO2009017719 A3 WO 2009017719A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
modulators
ccr9 receptor
compounds
ccr9
Prior art date
Application number
PCT/US2008/009142
Other languages
French (fr)
Other versions
WO2009017719A2 (en
WO2009017719A8 (en
Inventor
Eric C Anderson
Ronald J Biediger
Jie Chen
Brian Dupre
Pedro Lory
Robert V Market
Keith A Monk
Michael M Savage
Reginald Tennyson
Brandon M Young
Original Assignee
Encysive Pharmaceuticals Inc
Eric C Anderson
Ronald J Biediger
Jie Chen
Brian Dupre
Pedro Lory
Robert V Market
Keith A Monk
Michael M Savage
Reginald Tennyson
Brandon M Young
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Encysive Pharmaceuticals Inc, Eric C Anderson, Ronald J Biediger, Jie Chen, Brian Dupre, Pedro Lory, Robert V Market, Keith A Monk, Michael M Savage, Reginald Tennyson, Brandon M Young filed Critical Encysive Pharmaceuticals Inc
Priority to EP08794832A priority Critical patent/EP2220065A2/en
Priority to CA2692013A priority patent/CA2692013C/en
Priority to AU2008282903A priority patent/AU2008282903B2/en
Priority to MX2010001187A priority patent/MX2010001187A/en
Publication of WO2009017719A2 publication Critical patent/WO2009017719A2/en
Publication of WO2009017719A3 publication Critical patent/WO2009017719A3/en
Publication of WO2009017719A8 publication Critical patent/WO2009017719A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D333/40—Thiophene-2-carboxylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D333/70—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Provided are compounds that are modulators of CCR9 receptor activity, compositions containing the compounds and methods of use of the compounds and compositions. In certain embodiments, provided are methods for treating or ameliorating diseases associated with modulation of CCR9 receptor activity.
PCT/US2008/009142 2007-07-30 2008-07-28 Modulators of ccr9 receptor and methods of use thereof WO2009017719A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP08794832A EP2220065A2 (en) 2007-07-30 2008-07-28 Modulators of ccr9 receptor and methods of use thereof
CA2692013A CA2692013C (en) 2007-07-30 2008-07-28 Modulators of ccr9 receptor and methods of use thereof
AU2008282903A AU2008282903B2 (en) 2007-07-30 2008-07-28 Modulators of CCR9 receptor and methods of use thereof
MX2010001187A MX2010001187A (en) 2007-07-30 2008-07-28 Modulators of ccr9 receptor and methods of use thereof.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96264007P 2007-07-30 2007-07-30
US60/962,640 2007-07-30

Publications (3)

Publication Number Publication Date
WO2009017719A2 WO2009017719A2 (en) 2009-02-05
WO2009017719A3 true WO2009017719A3 (en) 2009-04-23
WO2009017719A8 WO2009017719A8 (en) 2010-02-11

Family

ID=40305125

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/009142 WO2009017719A2 (en) 2007-07-30 2008-07-28 Modulators of ccr9 receptor and methods of use thereof

Country Status (7)

Country Link
EP (1) EP2220065A2 (en)
KR (1) KR20100033418A (en)
AU (1) AU2008282903B2 (en)
CA (1) CA2692013C (en)
MX (1) MX2010001187A (en)
SG (1) SG183667A1 (en)
WO (1) WO2009017719A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA32965B1 (en) 2009-01-12 2012-01-02 Pfizer Ltd SULFONAMIDE DERIVATIVES
JP2013525368A (en) * 2010-04-23 2013-06-20 キネタ・インコーポレイテツド Antiviral compounds
JP5872552B2 (en) 2010-07-09 2016-03-01 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ Chemical compound
WO2012051318A1 (en) * 2010-10-12 2012-04-19 Zafgen Corporation Sulphonamide compounds and methods of making and using same
TW201512171A (en) 2013-04-19 2015-04-01 Pfizer Ltd Chemical compounds
EP4424681A1 (en) * 2021-10-28 2024-09-04 Shikoku Chemicals Corporation Thiophene compound, method for synthesizing same, and composition containing said thiophene compound

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998016520A1 (en) * 1996-10-16 1998-04-23 American Cyanamid Company The preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
JP2001002687A (en) * 1999-06-18 2001-01-09 Otsuka Pharmaceut Factory Inc Phosphonic acid diester derivatives
US20040180892A1 (en) * 2003-02-20 2004-09-16 Encysive Pharmaceuticals Inc. Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998016520A1 (en) * 1996-10-16 1998-04-23 American Cyanamid Company The preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
JP2001002687A (en) * 1999-06-18 2001-01-09 Otsuka Pharmaceut Factory Inc Phosphonic acid diester derivatives
US20040180892A1 (en) * 2003-02-20 2004-09-16 Encysive Pharmaceuticals Inc. Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE CAPLUS CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 9 January 2001 (2001-01-09), XP002515849, retrieved from STN Database accession no. 2001:18962 *

Also Published As

Publication number Publication date
SG183667A1 (en) 2012-09-27
CA2692013C (en) 2012-08-28
WO2009017719A2 (en) 2009-02-05
EP2220065A2 (en) 2010-08-25
AU2008282903B2 (en) 2011-06-30
MX2010001187A (en) 2010-03-04
AU2008282903A1 (en) 2009-02-05
CA2692013A1 (en) 2009-02-05
KR20100033418A (en) 2010-03-29
WO2009017719A8 (en) 2010-02-11

Similar Documents

Publication Publication Date Title
NL301145I1 (en)
MX2009006812A (en) Modulators of c3a receptor and methods of use thereof.
MX2007010560A (en) Roflumilast for the treatment of diabetes mellitus.
TN2010000122A1 (en) Compounds and compositions as modulators of gpr119 activity
PL2134704T3 (en) Compounds and compositions as modulators of gpr119 activity
IL192868A0 (en) 1,4-di substituted 3-cyano- pyridone perivatives and their use as positive mglur2-receptor modulators
MY145070A (en) Imidazolothiazole compounds for the treatment of disease
WO2006122156A3 (en) Compounds for modulating trpv3 function
IL232313A (en) Modulators of indoleamine 2,3-dioxygenase and methods of using the same
WO2009044173A3 (en) Methods of treating cancer using notch pathway inhibitors
PL1858877T3 (en) 1,3 substituted diaryl ureas as modulators of kinase activity
MX2010002028A (en) Methods and compositions for modulating t cells.
WO2010088450A3 (en) Arylamide derivatives useful in the treatment of diseases associated with serca activity
WO2009017719A3 (en) Modulators of ccr9 receptor and methods of use thereof
WO2007002188A3 (en) Mptenakts as modifiers of the pten/akt pathway and methods of use
WO2006050333A3 (en) Methods and compositions for modulating apoptosis
WO2006099183A3 (en) Nek8s as modifiers of the pten/akt pathway and methods of use
WO2008016996A3 (en) Methods of modulating metabolic memory
WO2009053895A3 (en) Quinoline urotensin-ii receptor antagonists
WO2007058860A3 (en) Mrhos as modifiers of the rho pathway and methods of use
UA97289C2 (en) Compounds and compositions thereof as grp119 activity modulators
SI1858877T1 (en) 1,3 substituted diaryl ureas as modulators of kinase activity
ME01506B (en) Modulators of indoleamine 2,3-dioxygenase and methods of using the same

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2692013

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2008282903

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2008794832

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 20107001995

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2010519223

Country of ref document: JP

Ref document number: MX/A/2010/001187

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2008282903

Country of ref document: AU

Date of ref document: 20080728

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1285/DELNP/2010

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: JP